Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Rapid cooling procedures prior to catheterization reduce extent of myocardial infarction

After an acute myocardial infarction, patients treated with rapid lowering of body temperature by combined cold saline infusion and endovascular cooling had less heart muscle damage and reduced incidence of heart failure. Therapeutic hypothermia was especially protective against heart muscle damage in patients with a large area of myocardium at risk according to an analysis of two clinical trials published in Therapeutic Hypothermia and Temperature Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

10 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Led by internationally-recognized cardiologists who are leaders in their field, the Peter Munk Cardiac Centre today announces the creation of an initiative to break ground in the cause, treatment and ongoing care of patients with an inherited, irregular heartbeat triggered by a rare cardiac structural condition.

30 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

New hope for patients suffering from most severe forms of anorexia nervosa

Anorexia Nervosa has the highest mortality rate of any mental illness. In its most severe form, victims face a devastating 4,500% increased risk for death. In the wake of the recent national attention on the limited treatment options available for these extreme cases, it is important for sufferers to know that help is available.

24 May 2015

Elderly cardiac patients receive less evidence-based treatment compared to younger patients

People in their 80s and 90s are more likely to develop acute coronary syndrome than their younger counterparts. Despite this, they receive less therapy and diagnostic procedures. A doctoral thesis at Sahlgrenska Academy has explored the topic.

14 May 2015

Powerheart G5 AED era arrives in the U.S. and Canada

Cardiac Science, an Opto Circuits group company and a global leader in AEDs, is proud to announce today that the Powerheart G5 AED era has arrived in the United States and Canada, representing both a technological milestone in the AED industry and the company's latest tool in fighting the world's No. 1 killer: sudden cardiac arrest (SCA).

12 May 2015

Study: Therapeutic hypothermia offers little neurological benefit to children with cardiac arrest

A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.

27 Apr 2015

Emergency body cooling, therapeutic hypothermia yield similar outcomes for children with cardiac arrest

A large-scale, multicenter study has shown that emergency body cooling does not improve survival rates or reduce brain injury in infants and children with out-of-hospital cardiac arrest more than normal temperature control.

27 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Ultrasound settings can change beat frequency of cardiac cells

Ultrasound—the technology used for sonograms and examining the heart—can increase the rate at which heart cells beat, researchers from Drexel University report.

24 Apr 2015

Majority of patients who survive cardiac arrest experience cognitive problems

Half of all patients who survive a cardiac arrest experience problems with cognitive functions such as memory and attention.

17 Apr 2015

Administration of selenide protects heart tissue post cardiac arrest, shows study

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center.

10 Apr 2015

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.

30 Mar 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

NIH awards K23 grant to study effects of carbon dioxide levels after cardiac arrest

The NIH-National Heart Lung and Blood Institute has awarded Brian W. Roberts, MD, emergency medicine physician at Cooper University Health Care and Assistant Professor of Emergency Medicine at Cooper Medical School of Rowan University (CMSRU), a Mentored Patient-Oriented Career Development grant (K23) to study post-resuscitation partial pressure of arterial carbon dioxide and neurological outcome after cardiac arrest.

25 Mar 2015

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014.

16 Mar 2015

Accidental fentanyl exposure in children can be fatal

Infants and children are at a higher risk of accidental exposure to fentanyl patches—adhesive patches used to deliver higher doses of some opiates through the skin to relieve chronic pain.

4 Mar 2015

Discoveries by WA research team offer further treatment hope for victims of stroke

A West Australian research team has made a series of discoveries which may help to minimise the damage that a stroke can cause.

20 Feb 2015

Meridian Health to celebrate American Heart Month, raise awareness for women's heart health

For the seventh year in a row, Meridian Health's Red Dress event will celebrate American Heart Month and raise awareness for women's heart health. The fun-filled, health-focused event will take place at Watermark, a chic lounge in Asbury Park. In partnership with The Heart Truth campaign, sponsored by the National Heart, Lung and Blood Institute, Meridian CardioVascular Network's Red Dress event will showcase fashions from the famous Red Dress Collection.

18 Feb 2015

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Rapid cooling procedures prior to catheterization reduce extent of myocardial infarction

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

New hope for patients suffering from most severe forms of anorexia nervosa

Elderly cardiac patients receive less evidence-based treatment compared to younger patients

Powerheart G5 AED era arrives in the U.S. and Canada

Study: Therapeutic hypothermia offers little neurological benefit to children with cardiac arrest

Emergency body cooling, therapeutic hypothermia yield similar outcomes for children with cardiac arrest

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Ultrasound settings can change beat frequency of cardiac cells

Majority of patients who survive cardiac arrest experience cognitive problems

Administration of selenide protects heart tissue post cardiac arrest, shows study

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

NIH awards K23 grant to study effects of carbon dioxide levels after cardiac arrest

Egalet announces net revenues of $1.9 million for 2014

Accidental fentanyl exposure in children can be fatal

Discoveries by WA research team offer further treatment hope for victims of stroke

Meridian Health to celebrate American Heart Month, raise awareness for women's heart health

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in